The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Outcomes of patients with stage IIIb cardiac AL amyloidosis treated with dara-CyBorD
Rajshekhar Chakraborty, MD, Columbia University Irving Medical Center, New York City, NY, comments on the results of a retrospective study investigating the efficacy of daratumumab plus cyclophosphamide-bortezomib-dexamethasone (dara-CyBorD) in patients with newly diagnosed stage IIIb cardiac AL amyloidosis. Whilst the study reported a promising efficacy signal in terms of hematologic response rate (RR), complete response (CR) rate, and cardiac response, a significant number of patients experienced grade 3 or higher infections. In addition, the study reported a high early mortality rate which highlights the need for more effective treatment strategies in this patient population. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
Disclosures
Consulting or Advisory Role: Janssen, Sanofi Pasteur, Adaptive Biotechnologies
